Article
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Molecular cancer therapeutics - 1 Aug 2016
Peh Jessie, Fan Timothy M, Wycislo Kathryn L, Roth Howard S, Hergenrother Paul J
Abstract excerpt
The development of vemurafenib resistance limits the long-term efficacy of this drug for treatment of metastatic melanomas with the (V600E)BRAF mutation. Inhibition of downstream MAPK signaling with vemurafenib induces apoptotic cell death mediated by caspase-3, suggesting that addition of a procaspase-3 activator could enhance anticancer effects. Here, we show that the combination of PAC-1, a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.